ArticleEpilepsia2025
Patterns of phosphorylated tau accumulation in a spectrum of acquired and developmental brain lesions associated with refractory epilepsy.
Article in Epilepsia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
objectivePhosphorylated tau (pTau) has been reported in surgical resections in refractory epilepsy. It is unclear whether this is activity-driven physiological pTau or signifies the advent of neurodegenerative cascades, relevant to memory decline. To date, primarily hippocampal sclerosis and focal cortical dysplasia (FCD) type II have been studied. We aimed to explore pTau in a range of acquired and developmental epileptogenic pathologies to assess its prevalence and identify potential drivers.
methodA total of 104 cases were studied representing FCD IA (n = 11), FCD IIIA (n = 5), FCD IIIB (n = 6), cavernoma (n = 11), Sturge-Weber leptomeningeal angiomatosis (n = 10), meningioangiomatosis (n = 4), perinatal infarcts (n = 9), Rasmussen encephalitis (RE; n = 6), gray matter heterotopia (n = 6), old scars (n = 10), and temporal lobe encephaloceles (n = 7); we also included focal microinjuries following prior stereoelectroencephalography at different ages (n = 19; four in lesion-negative cases). pTau was evaluated with AT8 immunohistochemistry, with further multiplex panels of AT8 with other established pTau markers (AT100, AT180, PHF1, CP13), pS6, glial fibrillary acidic protein, reelin, calbindin, and Tbr1 in selected cases. Labeling in the lesion was compared with adjacent cortex and clinical factors such as epilepsy duration.
resultspTau was identified in low to moderate levels in 60% overall, mainly localized to the epileptogenic lesion and more frequent in vascular malformations (74%-100%). pTau was noted in the superficial cortex across pathologies including encephaloceles, associated with superficial gliosis. In perinatal infarcts, distinct pTau patterns were noted in the superficial ulegyric cortex and heterotopic neuronal islands. Glial pTau was rare, and FCD IA, FCD IIIA/B, and microinjuries were negative. Variable regional expression of AT8 and mTOR activation markers (pS6) was noted, including in one RE case. Higher pTau expression was associated with older age at surgery and at onset of epilepsy, suggesting additional age-related vulnerability. SIGNIFICANCE: Our findings highlight localized and distinct patterns of pTau in some epilepsy pathologies. Plausible pathomechanisms include local vascular insufficiency, neuronal dysmaturation, and aging as well as seizure activity and provide direction for future exploration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.